Svas Biosana SpA

(Alliance News) - Svas Biosana Spa announced Monday that it has completed the acquisition of 100 percent of Hermes Pharma Doo and Megapharm Doo. The transaction on Hermes Pharma, carried out through its subsidiary Mark Medical, had a cost of EUR3.5 million, with a variable earn-out of up to EUR250,000, of which EUR148,200 has already been paid. Hermes Pharma ended 2023 with revenues of EUR4.9 million, Ebitda of EUR780,000 and net income of EUR540,000, with a negative net financial position of EUR300,000. The acquisition of Megapharm, carried out through Levante HC Holding, was completed for EUR3 million, with an earn-out of up to EUR250,000, of which EUR124,900 has already been disbursed. Megapharm reported 2023 revenues of EUR2.98 million, Ebitda of EUR630,000 and net income of EUR500,000, with a negative net financial position of EUR530,000. Svas Biosana's stock is flat at EUR7.40 per share.